

From: Melendez, Crystal
To: Sophia Siu
Cc: Fisher, Adriane (Adriane.Fisher@fda.hhs.gov)
Bcc: Price, Graeme
Subject: 125703.0_Kite Pharma, Inc._Advice
Date: Thursday, May 28, 2020 6:45:00 PM
Attachments: image001.png

Hello Sophia,

On 5/15/20 , applicant requested clarification on the FDA's definition of neurologic events. Please see below FDA responses(in blue)

Additional Kite Request for Clarification

1. In the documents provided by FDA in IR#27, we note that FDA has included the following additional terms as events flagged for inclusion as a NE:

Peripheral sensory neuropathy

Neuropathy peripheral

Gait disturbance

Diplopia

Vision blurred

Tinnitus

Papilloedema

Paresthesia oral

Nerve injury

Intensive care unit acquired weakness

Is it FDA's intent for the HGLT Peripheral Neuropathies to no longer be excluded, and for the 10 terms above to be added to Kite's analysis definition of NEs?

FDA response:

Neurologic events include the following terms: gait disturbance, diplopia, vision blurred, tinnitus, papilloedema, nerve injury, and Intensive care unit acquired weakness.

As stated, FDA's Neurotoxicity definition includes MedDRA SOC of Psychiatric disorders and Nervous system disorders. HLGT Sleep disorders and disturbances, Sleep disturbances (incl subtypes), and peripheral neuropathies are excluded. However, FDA's review find that some adverse events are divided, and missed; therefore, the reviewer utilizes both MedDRA SOC and a grouping strategy for comprehensive analyses of NE

2. In our review of the FDA events not flagged for inclusion as a NE, it appears that FDA wishes to exclude in the definition of NEs, the following terms:

Presyncope

Restless legs syndrome

Personality change

Dysgraphia

Dyskinesia

We respectfully request confirmation that the aforementioned revisions reflect FDA's intention with regard to the defined NE group. We especially draw your attention to the removal of dysgraphia, which seems to represent a neurologic event associated with chimeric antigen receptor T-cell therapy.

FDA response:

Dysgraphia is included in the NE group. The reviewer has utilized a grouping

strategy for comprehensive analyses of AEs. Please refer to the word document sent to KITE on 13 May 2020,(that) includes all the grouped terms use for the adverse events.

Please confirm receipt.

Regards,

Crystal Melendez, MT, RN, BSN

Regulatory Project Manager

U.S. Food and Drug Administration

Center for Biologics Evaluation and Research

Office of Tissues and Advanced Therapies

10903 New Hampshire Avenue

Silver Spring, MD 20993

Bldg.71, 4268

Tel: 240-402-8348

Wk cell: 240-772-6272

crystal.melendez@fda.hhs.gov

DRPM, Achieving Regulatory Excellence!

New - COVID-19 CBER Regulated Biologics

THIS MESSAGE IS INTENDED FOR THE USE OF THE PARTY TO WHOM IT IS ADDRESSED AND MAY CONTAIN INFORMATION THAT IS PRIVILEGED, CONFIDENTIAL, AND PROTECTED FROM DISCLOSURE UNDER LAW. If you are not the addressee, or a person authorized to deliver the document to the addressee, you are hereby notified that any review disclosure, dissemination, copying, or other action based on the content of this communication is not authorized. If you have received this document in error, please immediately notify us by email or telephone found above.

This communication is consistent with 21 CFR 10.85(k) and constitutes an informal communication that represents my best judgment at this time but does not constitute an advisory opinion, does not necessarily represent the formal position of FDA, and does not bind or otherwise obligate or commit the agency to the view expressed